[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645230":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":38,"collaborators":7,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":7,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":7,"enrollmentInfo":49,"targetDuration":7,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"HK inno.N Corporation","INDUSTRY",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"yong an jeong","CONTACT","82-31-5176-4673","yongan.jeong@inno-n.com",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"seung gye cho","82-31-5176-4676","seungkye.cho@inno-n.com",[19],{"facility":20,"status":21,"city":22,"state":7,"zip":7,"country":23,"countryCode":7,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"HK inno.N","RECRUITING","Seoul","South Korea",{"type":25,"coordinates":26},"Point",[27,28],126.9784,37.566,{"lat":28,"lon":27},[31,34],{"name":32,"role":11,"phone":33,"phoneExt":7,"email":17},"Seung Kye Cho","+82 31 5176 4676",{"name":35,"role":11,"phone":36,"phoneExt":7,"email":37},"Ahrong Kim","+82 31-5176-4666","ahrong.kim@inno-n.com",{"type":39,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100645230","an-observational-study-to-evaluate-the-efficacy-and-safety-of-k-cab-tabk-cab-odttegoprazan-in-gerd-patients-100645230",false,"NCT07678177","An Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab.\u002FK-CAB ODT(Tegoprazan) in GERD Patients","A Multi-center, Prospective, Observational Study to Evaluate the Safety and Efficacy of K-CAB Tab.\u002FK-CAB ODT(Tegoprazan) in GERD Patients","Inclusion Criteria:\n\n1. Subjects over 19 years of age as of the date of consent\n2. Subjects with a total score of 8 or more in the Korean Gastroesophageal Reflux Disease Questionnaire (GerdQ) based on Visit 1\n3. Subjects who voluntarily decides to participate and agrees in writing to the consent form of the study\n\nExclusion Criteria:\n\n1. Subjects who have hypersensitivity reactions and a medical history of Benzimidazole or components of the investigational drug\n2. Subjects on Atazanavir, Nelfinavir, or Rilpivirine-containing medications\n3. Pregnant and lactating women","ALL","19 Years",{"count":50,"type":51},5384,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the status of AE and improvement effect of K-CAB Tab\u002FK-CAB ODT(Tegoprazan) 50mg in patients with GERD.",[55],"GERD (Gastroesophageal Reflux Disease)",[57],"IN_TPZ_N03","2026-06-25",{"date":60,"type":61},"2026-07-01","ACTUAL",{"date":63,"type":61},"2023-03-07",{"date":65,"type":51},"2027-06-30",{"name":5,"class":6},1]